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ABSTRACT
Impact of Collateral Enlargement on Smooth Muscle Phenotype
Alexander Bynum
Peripheral Artery Disease is a very serious disease characterized by an arterial occlusion
due to atherosclerotic plaques. In response to an arterial occlusion, arteriogenesis occurs,
causing smooth muscle cells to transition from a contractile to synthetic state. Also
following an arterial occlusion, functional impairment was seen in the collateral circuit.
An immunofluorescence protocol was developed in order to assess the impact of
collateral enlargement (arteriogenesis) on smooth muscle phenotype at various time
points. Smooth muscle α-actin was used to mark all smooth muscle cells, Ki-67 was used
to label proliferating smooth muscle cells, and a fluorescent nuclear stain was used to
quantify the number of cells present. Samples of the profunda femoris and gracilis were
dissected from each mouse hind limb (one ligated, one sham) at three different time
points: 3 days, 7 days, and 14 days after a femoral artery ligation surgery. Smooth muscle
cell phenotype and luminal cross-sectional area were assessed in the profunda femoris
and the midzone of the gracilis collaterals. Smooth muscle cells were proliferating at 3
and 7 days following the occlusion in the gracilis collaterals and significant collateral
vessel growth was observed over the two week period. No proliferation was observed in
the profunda femoris and although there was an increasing trend in vessel size over the
two week period, the averages were not significantly different. The phenotypic transition
of the smooth muscle cells was not the cause of vascular impairment in the collateral
circuit. This shows that further research is needed to characterize impairment in the
collateral circuit.
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Introduction

Introduction
Normal Vascular Anatomy and Function
The Circulatory System
The circulatory system supplies the body’s tissue with oxygen and nutrients while
simultaneously removing carbon dioxide and other waste products for excretion by the
lungs and kidneys. This exchange of gases, water, and solutes between the vascular and
interstitial fluid compartments occurs mainly in the capillaries, in which the vessel wall
consists of a single endothelial cell and associated perivascular cells. While distributing
essential substances to the tissues and removing the by-products of metabolism, the
circulatory system also maintains homeostasis through evaporative cooling, delivering
endocrine products, and adjusting oxygen and nutrient supply for different physiological
states [1].
The heart that supplies this circulatory system is comprised of two pumps, or ventricles,
in series. The right ventricle works to propel blood through the lungs for exchange of
oxygen and carbon dioxide; this is referred to as the pulmonary circulation. The left
ventricle works to propel blood to all other tissues of the body, the systemic circulation.
From the heart, the blood is pumped into the aorta, the largest of the arteries. After the
blood moves from the aorta into the large network of arteries, it flows into small arteries
and arterioles, which are the resistance vessels of the circulation. The diameter, or
vascular tone, of these vessels, coupled with the output of the left ventricle, determine the
distribution of the circulation. Once blood leaves these arterioles, it moves into the
capillaries for nutrient and waste exchange. Once blood leaves the capillaries it enters the
1
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network of venules followed by the larger veins, and finally the largest vein, the vena
cavae. From the vena cavae, the blood flows back into the heart to be pumped into the
lungs. This unidirectional flow through the heart is achieved by the appropriate
arrangement of valves. Although the cardiac output is intermittent, continuous flow to the
periphery occurs by distension of the aorta and its branches during ventricular contraction
(systole) and elastic recoil of the walls of the large arteries with forward propulsion of the
blood during ventricular relaxation (diastole). After the blood flows from the heart into
the aorta, a predominantly elastic structure, the peripheral arteries become more muscular
until the muscular layer predominates at the arterioles [1].
In a normal intact circulation, the total volume of blood is constant, and an increase in the
volume of blood in one area must be accompanied by a decrease in another. This
distribution of the circulating blood to the various regions of the body is determined by
the vascular tone of the resistance vessels (small arteries and arterioles) in these regions.
The circulatory system is composed of these various conduits arranged in series and in
parallel as displayed in Figure 1 [1].

2
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Figure 1 Schematic diagram of the parallel and series arrangement of the vessels
composing the circulatory system[1].

Between the aorta and the capillaries, the number of vessels increases up to 3 billion-fold,
and the total cross-sectional area increases about 500-fold. The volume of blood in the
systemic vascular system is greatest in the veins and venules, which contain about 67%
of the body’s blood during rest. Only 5% of the total blood volume is located in the
capillaries and only 11% of the blood is contained in the aorta, arteries, and arterioles
collectively. In contrast, blood volume in the pulmonary vascular bed is about equally
divided among the arterial, capillary, and venous vessels [1].
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Smooth Muscle Cell Function in the Arterial Network
Smooth muscle cells (SMCs), are inherently important to the circulation because of their
role in the regulation of vascular tone (i.e. blood pressure and blood flow control).
Although SMCs are located in all vessel walls, vascular tone and the distribution of blood
are determined by the contractile state of SMCs within the arteriole and small/muscular
artery wall.
While smooth muscle cells are different than cardiac or skeletal muscle cells, they do
have many individual similarities to striated muscle. For instance, smooth muscle cells
contain many of the same types of organelles and contractile proteins that can be found in
skeletal muscle. Unlike skeletal muscle, embryonic smooth muscle cells do not fuse, and
each differentiated cell has a single, centrally located nucleus. SMCs are typically 40 to
600 µm long and are 2 to 10µm in diameter in the region of the nucleus, with most cells
exhibiting a spindle shape [4].
There are various types of smooth muscle cells that can be categorized based on their
method of stimulation, their level of connection with other SMCs, or their activity
patterns. Vascular smooth muscle cells (VSMCs), in particular, are considered multiunit
SMCs because most are not electrically coupled. This means that the stimulation of one
cell does not necessarily result in activation of adjacent cells. This is in contrast to single
unit SMCs, in which all cells are electrically coupled, resulting in consecutive stimulation
of adjacent cells (e.g. SMCs in the gut during peristalsis). VSMCs can also be classified
as tonic smooth muscle cells because they are, at times, continuously active [4]. During
tonic contraction, myoplasmic Ca++ and cross-bridge phosphorylation decline after an
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initial spike followed by a slow increase in force, eventually tapering off at a high level.
Referred to as the “latch state,” this sustained force is maintained with only 20% to 30%
of the cross-bridges phosphorylated, and thus ATP utilization is reduced. Smooth muscle
cells use 300-fold less ATP than would be required by skeletal muscle to generate the
same force with fatigue only occurring if the cells are deprived of oxygen [4].
The contractile state of vascular smooth muscle cells within the arteriole and
small/muscular artery wall is regulated by intercellular calcium concentration [5]. A rise
in intercellular calcium is usually due to an action potential or the presence of a
hormone/agonist. This rise in intracellular [Ca2+] results in the binding of [Ca2+] ions to
calmodulin, creating a complex that activates myosin light-chain kinase (MLCK), which
phosphorylates the regulatory light chain of myosin [4]. This phosphorylation, along with
an ATP molecule to energize each myosin cross-bridge, is critical for the interaction of
smooth muscle myosin and actin in the development of force [4]. When myoplasmic
[Ca2+] falls, MLCK becomes inactive, and the cross-bridges are dephosphorylated (i.e.
cross-bridge cycling stops) [4]. This myosin cross-bridge cycling is similar to that of
striated muscle in that it involves a ratcheting action of the myosin head that pulls the thin
filament toward the center of the thick filament, causing a generation of force. However,
the kinetics of cross-bridge cycling is slower for smooth muscle cells, and unlike striated
muscle, cannot occur if the regulatory light chain of myosin is not phosphorylated [4].
Also, in contrast to striated muscle, the sensitivity of contraction to [Ca2+] is variable in
smooth muscle, in that different agonists can increase the force of contraction at
submaximal levels of intracellular [Ca2+] [4].
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A variety of drugs and hormones relax smooth muscle by increasing the cellular
concentrations of cyclic nucleotides, such as cGMP. Soluble guanylyl cyclase (sGC), a
receptor for nitric oxide (NO), produces cGMP. Increases in cGMP promote the
activation of protein kinase G, which inactivates myosin light chain kinase, causing the
actin-myosin cross-bridge cycling to cease [4]. So, by increasing cGMP, NO, produced
by nerves and vascular endothelial cells, relaxes smooth muscle [4]. A reduction in
intracellular [Ca2+], associated with the relaxation of smooth muscle, is usually via
stimulation of [Ca2+] pumps in the sarcolemma, the sarcoplasmic reticulum (SR) or both
[4]. Acetylcholine released from parasympathetic fibers also causes vasodilation in some
vascular beds as a result of the production of NO by vascular endothelial cells [4].
Vasoconstrictors and vasodilators use two methods, often simultaneously, to stimulate
contraction and dilation, respectively. They can adjust sensitivity to [Ca2+] or change the
levels of intracellular [Ca2+] in VSMCs. In contrast, an elevation in endothelial [Ca2+]
induces relaxation of the adjacent VSMCs. Therefore, fine tuning of [Ca2+] in both cell
types is imperative for precise regulation of organ and tissue perfusion [5].
The contractile activity of SMCs are systemically controlled by the autonomic nervous
system, specifically, vascular smooth muscle cells are primarily innervated by
sympathetic fibers [4]. Sympathetic fibers, using norepinephrine (NE) as a
neurotransmitter, stimulate α1-adrenergic receptors on VSMCs. Binding of NE causes the
G protein dependent activation of phospholipase C (PLC), which results in the production
of inositol 1,4,5-triphosphate (IP3). Elevated levels of IP3 activates the IP3-gated [Ca2+]
channel in the SR, which results in an increase of myoplasmic [Ca2+] and leads to
vasoconstriction [4]. Although VSMCs are primarily controlled by adrenergic
6
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stimulation, their contractility is still susceptible to muscarinic stimulation via
acetylcholine, as mentioned above [4]. The tone of the SMCs, as discussed above, is
subject to local influence from circulating hormones and neighboring endothelial and
skeletal muscle cells via diffusable substances such as NO and adenosine [4]. VSMC tone
can also be stimulated by physical stretch, a phenomenon called the myogenic response.
VSMCs will contract in response to an increase in transumural pressure stretch and relax
in response to a decrease in transmural pressure [1]. An initial flow increment produced
by an abrupt increase in perfusion pressure that passively distends the blood vessels
would be followed by a return of flow to the previous control by contraction of the
VSMCs in the resistance vessels [1].
Smooth muscle function can be controlled systemically or locally, via the nervous
system, endocrine system, or physical stretch. These alterations in smooth muscle
contractility and vascular tone facilitate adjustments in blood flow in order meet the
oxygen demands of various parts of the body on an acute basis [4].

Vasculature Adaptations
Acute changes in blood flow are brought on by vascular responses such as a change in
smooth muscle contractility and vascular tone. However, if blood flow is consistently
altered, the vessel will experience chronic changes (i.e. vascular adaptations). Arterial
occlusion is a common stimulus for chronic changes in blood flow. An arterial occlusion
induces both angiogenesis, the sprouting of the capillaries, as well as arteriogenesis, the
growth/remodeling of pre-existent arterioles into conduit arteries [6].
7
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Interarterial connections associated with arteriogenesis are called collateral vessels or
anastomoses [6]. These vessels are present in almost all organs. During arteriogenesis,
the vessels can enlarge to an astonishing degree and can function under favorable
conditions as efficient blood conductors preventing or limiting tissue necrosis [6].
Physical factors such as fluid shear stress are well established as the initiating events of
arteriogenesis. Although angiogenesis plays an important role in the adaptation to arterial
occlusion due to hypoxia in the downstream tissue, arteriogenesis is more efficient at
restoring blood flow [6]. It has been shown that arteriogenesis can also prevent
angiogenesis by restoring blood flow to the ischemic tissue and that ischemia is not the
direct driving force in arteriogenesis [6].

Angiogenesis
Although angiogenesis is a normal vascular adaptation, it also occurs in many diseases,
including cancer, diabetic retinopathy, and atherosclerosis. Anti-angiogenic agents have
entered clinical use for cancer and eye disease and angiogenesis has been proposed as a
treatment for of ischemic diseases [7].
Angiogenesis occurs through multiple, complementary roles in normal or pathological
angiogenesis [7]. Pathological angiogenesis often occurs in response to hypoxia which
causes endothelial cells and parenchymal cells to increase the transcription of hypoxiainducible factor-1 (HIF-1), which upregulates vascular endothelial growth factor (VEGF)
[8]. As a result of an increase in VEGF, proteolytic degradation of the extracellular
martrix occurs, followed by chemotactic migration and proliferation of endothelial cells,
8
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the formation of a lumen, and the functional maturation of the endothelium [8]. The result
of this sprouting angiogenesis is a newly formed capillary loop in the once hypoxic
tissue.
Arteriogenesis
Arteriogenesis is the process whereby a preexisting arteriole outwardly remodels into a
conductance artery. An example would be in the case of an occlusion of the femoral
artery in the mouse hindlimb. Collateral vessels enlarge in the upper leg between
proximal and distal side branches, relatively close to the site of occlusion (due to the
large changes in hemodynamics) [3]. In contrast, ischemia induces hypoxia in the lower
leg and the foot, which causes angiogenesis to occur [3].

Figure 2 Laser Doppler image of collateral blood flow in an anesthetized
mouse with exposed upper thigh skeletal muscles with chronic occlusion
(7days) of the left femoral artery [3].
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As we can see from Figure 2, the superficial adductor muscles in the murine upper leg
have a dual arterial blood supply. Different side branches enter the muscle from both
medial and lateral ends and taper down; the primary arterioles from both side branches
meet and connect in the middle of the muscle, forming an anastomosis [3].
The collateral vessel is associated with three different zones: the stem, mid-zone and
reentry. The stem is characterized by the feed vessel to the collateral (the profunda
femoris in Figure 2). The mid-zone is characterized by the middle of the collateral,
where the greatest degree of arteriogenesis usually occurs post occlusion (the gracilis
collaterals in Figure 2). Reentry is the area where the collateral supplies blood flow
downstream of the occluded vessel (where the gracilis collateral meets the saphenous
artery in Figure 2).
As a result of an arterial occlusion, the rerouting of blood in the collateral circuit causes
an increase in shear stress on the vessel wall. These changes in wall stress and shear
stress are sensed by the endothelium, which up-regulates growth factors and secrete nitric
oxide (NO) and prostacyclin [3]. Eventually the chronic increased shear stress causes the
activated endothelium to lose volume control and swell [3]. When this mechanical force
is transmitted from the deformed cell it will activate transcription factors, such as egr-1,
which will up-regulate chemokines like MCP-1 and adhesion molecules like intracellular
adhesion molecule-1 (ICAM-1), which are necessary monocyte docking [3]. Monocytes
are crucial to facilitating arteriogenesis and suppression of them significantly delaya
arteriogenesis [3].
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The midzone of growing collaterals is surrounded by a perivascular inflammatory
infiltrate, consisting mainly of monocytes and T-lymphocytes. These cells have migrated
partially from the arterial lumen. The media of these vessels is thus surrounded from both
sides by inflammatory cells that secrete growth factors and proteases that are necessary to
remodel the old media. T-lymphocytes are also necessary to destroy cells in the close
vicinity of the collateral artery to create the space to be occupied by the greatly expanded
vessel [3].
Remodeling begins after the acute phase of arteriogenesis, which is dominated by the
inflammatory events (i.e. endothelium activation and extravasation of monocytes and Tlymphocytes). The process begins with the upregulation of matrixmetalloproteinases
(MMPs), a type of protease that digests the extracellular matrix of the vessel wall and
provides space for new cells and enables SMCs to migrate away from the intima to create
a new, larger conductance vessel [3]. A new elastic lamina is synthesized by the smooth
muscle cells (SMCs), and the rebuilding of the media and the formation of an intima
begins with the upregulation of the tissue inhibitor of MMPs [3]. The role of SMCs in
arteriogenesis will be discussed later in more detail, as they are a key component in this
study.
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Perpherial Artery Disease and Atherogenesis
Perpherial Artery Disease (PAD), the most common cause of peripheral arterial occlusion
in patients, is characterized by fatty deposits in the inner linings of the artery walls. These
fatty deposits can restrict blood circulation to the periphery, causing the downstream
tissue to become ischemic, often leading to serious health problems in the individual.
PAD affects a large segment of the adult population, with an age-adjusted prevalence of
4% to 15%, affecting more than 5 million adults in the United States and increasing up to
30% with age and the presence of cardiovascular risk factors. Twenty percent of patients
with PAD have typical symptoms of intermittent leg-muscle discomfort on exertion,
ulceration or gangrene. Another third of patients have atypical exertional leg symptoms
[9].
Age and gender-adjusted risk factors associated with the development of PAD are similar
to the traditional risk factors for atherosclerosis, which include: cigarette smoking,
diabetes, hyperlipidemia, hypertension, hyperhomocystinemia and chronic renal
insufficiency [10]. Smoking and diabetes are the strongest risk factors and are associated
with more aggressive disease progression [9]. The relative risk of claudication is 3.7
times the normal risk in current smokers and 3 times in ex-smokers [11]. Also, the
presence of diabetes increases the risk of PAD by 2- to 4-fold with 5- to 10-times higher
need for major amputation in diabetics compared to non-diabetics [12].
Studies of the natural history of PAD indicate that the risk of ischemic limb events for
non-diabetic patients is relatively low, with less than 2% requiring major or minor
amputation. Although intermittent claudication can lead to less exercise, causing obesity,
12
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osteoporosis, etc., cardiovascular disease and manifestations of atherosclerosis in other
vascular beds are the major determinants of prognosis in these patients [9]. There is
approximately a 2- to 4-fold increase in coronary and cerebrovascular disease in patients
with PAD, with an annual rate of 5-7% for cardiovascular events (myocardial infarction,
stroke, or death from cardiovascular causes) [10]. Notably, the risk of cardiovascular
morbidity and mortality is similar in all patients with PAD, regardless of the presence of
symptoms [13]. Therefore, managements of the disease are directed not only at
improving symptoms of claudication and the lower limb ischemia, but more importantly
at reducing the overall cardiovascular risk [9].
Mechanisms Involved in the Development of Atherosclerotic Plaques
This build up of fatty deposits, or atherosclerosis, is characterized by lipid deposition and
inflammation in the artery wall. Cholesterol is the major lipid species in artherosclerotic
lesions and accumulates in both unesterfied and esterfied forms [14].
Atherosclerosis is also characterized by plaques consisting of necrotic cores, calcified
regions, accumulated modified lipids, inflamed smooth muscle and endothelial cells,
leukocytes, and foam cells. As described, atherosclerosis is a disease that involves
components of the vascular, metabolic, and immune systems [2].
The occurrence of inflammatory cells in atherosclerotic lesions depends on the rate of
their recruitment and egress and the balance of proliferation, survival, and apoptosis
within the arterial wall [2]. The following figure diagrams the mechanisms involved in
the development of atherosclerosis.
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Figure 3 Immune and inflammatory cells in atherosclerosis[2].

The endothelial cells above the lesion are polygonal in shape, whereas the normal
endothelial cells are aligned with the direction of flow [2]. Also, the normal intima is
usually very thin, and would be almost invisible except at the highest resolutions, but the
neointima is greatly expanded in the lesion area [2]. In this area, there are vascular
dendritic cells, macrophages, foam cells, and T lymphocytes [2]. The foam cells surround
the necrotic core, which is composed of foam cells that have undergone necrosis [2]. The
normal media is populated by smooth muscle cells that are organized between an internal
and external elastic laminae. Myeloid cells invade the media in the lesion area, while the
14
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normal adventitia is populated by sparse T cells, B cells, lymphocytes, and dendritic
cells. In the lesion area, lymphocytes induce an angiogenesis in the vasovasorum that is
thought to destabilize plaque and precipitate rupture events [2].
Diagnosis and Management of PAD
Atherosclerosis eventually leads to a reduced blood flow distal to the injury, causing
ischemia in the downstream tissue. Although there are no cures for this disease, there are
ways to diagnose and manage the symptoms. Initial evaluations include a careful history
and physical examination with shoes and socks removed to assess for signs of acute or
chronic peripheral ischemia, with attention to peripheral pulses, hair loss, skin color, and
trophic skin changes [9]. The abdomen is also examined for evidence of an aortic
aneurysm and blood pressure is measured in both arms[9]. Also, a stethoscope is used to
check for sounds of turbulent flow at the neck, and over the clavicles, as well as pulses in
the abdomen and femoral region [9]. Upon clinical suspicion for PAD, referral to a
vascular laboratory is the initial step for noninvasive diagnostic assessment of the
location and severity of the arterial disease. These noninvasive tests can also be repeated
over time to follow the disease progression and response to medical treatment or
revascularization[9]. Some of these tests include ankle-brachial pressure measurement or
noninvasive imaging techniques [9].
In attempts to manage PAD, patients will undergo risk factor modification, an exercise
program, pharmacologic treatment, and endovascular or surgical revascularization. In
most cases, revascularization is reserved for patients experiencing significant disability.
Patient-specific managements may include smoking cessation programs, aggressive
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control of hyperglycemia, and lipid-lowering to reduce the risk of cardiovascular events
due to atherosclerosis [9].
Current treatments for PAD
Once PAD has been diagnosed, there are various treatments available. The extensiveness
of the treatment often depends on the progression of the disease in the patient. The most
efficacious treatment is exercise, which significantly improves walking time and overall
walking ability in patients with intermittent claudication [10]. Notably, exercise may be
more effective than antiplatelet therapy in improving maximal walking time and have
equivalent efficacy to surgery [10]. Furthermore, physical activity both prevents and
helps treat many established atherosclerotic risk factors, such as elevated blood pressure,
insulin resistance and glucose intolerance, elevated triglyceride concentrations and low
high-density lipoproteins [9]. Habitual physical activity also helps to reduce
inflammation, which is associated with the pathogenesis of atherosclerosis [9].
If there is a serious hindrance on a patient's quality of life, or they have a reduced
exercise capacity, antiplatelet therapy may be suggested. Antiplatelets are a class of drugs
that decrease platelet aggregation and inhibit thrombus formation. In patients at high risk
of arterial occlusive disease, antiplatelet therapy with aspirin reduces the risk of
myocardial infarction, stroke and cardiovascular death by 25% [15]. Although aspirin has
not been shown to improve claudication, it delays the progression of PAD, reduces the
need for intervention, and reduces graft failure in patients who have undergone surgery
[9]. Clopidogrel is another anti-platelet therapy that has been shown to reduce the risk of
myocardial infarction, stroke or cardiovascular death. Because aspirin is cheaper and
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easier to obtain, clopidogrel is currently only recommended as an effective alternative for
those who may be allergic to aspirin or other NSAIDs. There are also many other antiplatelet therapies available, but these are less beneficial than aspirin in patients with PAD
because of the associated increased risk of major bleeding in the patient [9].
If antiplatelet therapies are not sufficient, there are other pharmacological agents that
specifically treat claudication. Cilostazol is a proficient treatment for claudication
because it is a vasodilator with mild anti-platelet properties. Treatment with cilostazol
significantly increases maximal and pain-free walking distance and may improve the
quality of life in patients with PAD. Although there are other options to cilostazol, they
have been shown to be less effective at treating claudication [16].
Since there is often an inadequate response to exercise or the previously discussed
pharmacological therapies, researchers continue to search for new therapies. The use of
angiogenic growth factors, such as vascular endothelial growth factor (VEGF),
recombinant fibroblast growth factor 2 (rFGF-2) and hypoxia-inducible factor-1, have
generated considerable enthusiasm as potential treatments of PAD because of their role in
the stimulation of new vessel growth [9]. Clinical studies on delivering single growth
factors intramuscularly were not successful. Recent applications have effectively
integrated the use of gene transfer strategies of angiogenic proteins, but these applications
still prove ineffective [17]. More studies and trials need to be conducted to assess the
overall efficacy and safety of these growth factors [17].
Although exercise and pharmalogical treatments have proven to be somewhat effective at
combating the symptoms and slowing the progression of PAD, some patients may have
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more severe cases in which these methods prove ineffective [9]. With these patients,
endovascular treatments are often suggested. Endovascular techniques to treat PAD
include percutaneous transluminal angioplasty (PTA) with balloon dilation, endografts,
atherectomy, cutting balloons, drug-coated balloon angioplasty, cryoplasty, percutanoues
thrombectomy and brachytherapy [9]. From all of the therapies listed above, PTA is the
recommended initial endovascular treatment for PAD [10].
Endovascular stenting is also another form of treatment for PAD because it avoids the
problems of early elastic recoil, residual stenosis and flow-limiting dissection after
balloon angioplasty and thus can be used to treat long and calcified lesions. Although
stent designs continue to improve over the years, more data is required to improve
patency while reducing the chance of fracture [18].
Initial attempts have been made using newer technologies, such as drug-eluting stents and
balloons that have proved beneficial as percutaneous coronary intervention (PCI)
techniques. However, this technology has not yet been successful when used in the
peripheral arteries [19]. Aside from the previously described endovascular therapies,
there are still many emerging endovascular technologies. While these methods are
currently being investigated, their role in the treatment of PAD still remains controversial
[9].
As the population ages, it is anticipated that the prevalence of PAD will increase[9].
Although there has been a rapid evolution of technology for treatments, there are still
vital improvements that need to be made in the future. All non-interventional techniques
either treat symptoms or slow the disease and interventional techniques are often
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dangerous and complicated. While these treatments can slow the dangers associated with
the disease, there is still a need to better understand the progression of atherosclerosis. By
studying the development of atherosclerosis and its side-effects (e.g. impaired
vasodilation), we can develop new approaches that work towards either reversing the
progression atherosclerosis or restoring proper blood flow to ischemic tissues.

Impact of Ischemia on Vasculature
Impaired Vasodilation
While PAD is becoming more prevalent throughout our population, the root of the
problem is atherosclerosis and its co-morbidities (e.g. hypercholesterolemia) which are
known to impair the vasculature. Atherosclerosis is a systemic disease, therefore patients
with a clinical manifestation of a specific atherosclerotic disease (e.g. CAD) are likely to
have pathologically similar lesions in other vascular beds. As eluded to earlier, patients
who develop atherosclerotic occlusions experience impaired vasodilation in the collateral
circuit [20]. This supports the hypothesis that atherosclerosis systemically affects the
functional and morphological characteristics of several parts of the circulatory system.
Although ischemic disease is associated with impaired vasodilation, an arterial occlusion
alone also causes impairment [21]. This is supported by studies showing that vasomotor
responses of relatively large collateral vessels to vasodilators are impaired in ischemic
limbs of animal models in vivo[22].
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Vascular Smooth Muscle Phenotypes

There is speculation that impaired vasodilation following arterial occlusion is due to
arteriogenesis occurring in the collateral circuit. The transition of vascular smooth muscle
cells from a differentiated (contractile) to a dedifferentiated (synthetic, migratory)
phenotype plays a crucial role in the process of arteriogenesis. This phenotypic switch of
SMCs also plays a critical role in many other physiological and pathological processes,
including atherosclerosis, angiogenesis, smooth muscle hypertrophy, and hyperplasia
[23]. Smooth muscle cells display a plastic diversity, meaning they dynamically exhibit
distinct contractile and synthetic phenotypes with unique morphological, biochemical,
functional, and gene expression characteristics [24]. The contractile smooth muscles are
largely filled with contractile proteins and contain few subcellular organelles, while the
synthetic smooth muscles have more subcellular organelles (e.g. free ribosomes and
endoplasmic reticulum) involved in protein synthesis [25].

As mentioned above, a marked difference is found in the expression of cytoskeletal and
contractile proteins in these two phenotypes. Rabbit VSMCs can express at least three
types of myosin heavy chain isoforms: SM1, SM2, and SMemb [25]. SM1 and SM2 are
alternative RNA splicing products of a single gene and both are specifically expressed in
SMCs. SM1 is constitutively expressed from early development, but SM2 only appears
after birth. On the other hand, SMemb is predominantly expressed in embryonal and
neonatal aortas but is down-regulated in adults [25]. In addition to its abundance in the
brain vasculature, SMemb is expressed together with SM1 in SMCs undergoing growth
and/or cell division, such as embryonic SMCs of fetal aorta and proliferating SMCs in
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atherosclerotic neointima [26]. Based on these developmental characteristics, the myosin
heavy chain profiles are most useful in defining smooth muscle cell differentiation as
well as identifying abnormally proliferating smooth muscle cells in injured arteries [25].

VSMCs and their phenotypic transition are an integral step in the outward remodeling of
collateral vessels. Prior to the synthesis of a new elastic lamina by VSMCs, MMPs digest
the matrix and provide space for new cells and enable VSMCs to migrate toward the
intima. Many non-proliferative VSMCs of the old media apoptose and are replaced by
daughter cells of proliferative VSMCs [3]. Those that proliferate change their phenotype
and degrade most of their contractile proteins, which are replaced by expanded
endoplasmic reticulum and free ribosomes, an indication of their synthetic activity. The
loss of the contractile phenotype is ascribed to the combined activities of protein kinase
G, activin, and RGs-5 [3]. In addition to actin and myosin, desmin and calponin are
downregulated and fibronectin is upregulated [3]. The thickening of the vessel wall
occurs under markedly increased tangential wall stress causing the intercellular
connections and the communication between cells to change. This is paralleled by the
strongly induced expression of connexin 37 in VSMCs, which is an early marker for
arteriogenesis that is normally not expressed in VSMCs and only weakly in endothelium
[3].
It is hypothesized that smooth muscle cell proliferation and migration, and the inability
for the cells to relax and contract could be the reason for vascular impairment during a
post-occlusion arteriogenic event.
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Summary
It is proficiently documented that patients with PAD or other ischemic diseases
experience reduced blood flow to tissues distal of an atherosclerotic occlusion [10]. In
addition to this, ischemic disease is typically coupled with an impaired vasculature
characterized by reduced vascular reactivity [21]. In order to eventually understand the
underlying mechanisms of dysfunction in patients with PAD, we must start by assessing
vascular adaptations in simple animal models. This will help us determine the effects of
the different responses to an arterial occlusion. We have chosen to study arteriogenesis
first because it is thought to be critical for limb salvage and groups are currently trying to
develop new therapies to stimulate this process. We hypothesize that smooth muscle
cells, in their transition from a contractile to a synthetic state in response to vascular
injury, are the cause of impaired vasoactivity observed in animal models. These studies
will be a precursor for tailoring therapies to either stimulate vascular reactivity or to work
around the area of impaired vasculature (i.e. arteriogenesis) in order to supply the
ischemic tissue with adequate blood flow in patients with PAD.
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Specific Aims
In response to an arterial occlusion, arteriogenesis occurs, causing smooth muscle cells to
transition from a contractile to synthetic state. Also following an arterial occlusion,
functional impairment was seen in the collateral circuit. During this transition, smooth
muscles cells proliferate and migrate, and in the process it is thought that they lose their
ability to contract and relax efficiently. We hypothesize that this phenotypic transition of
smooth muscle cells is the cause of impaired vasoactivity following arterial occlusion.
We will assess the vasculature following an occlusion to understand the impact of
arteriogenesis on smooth muscle proliferation.


Specific Aim 1 - Develop immunohistochemistry and immunofluorescence
protocols to assess smooth muscle cell proliferation and determine vessel crosssectional area.



Specific Aim 2 - Determine the impact of an arterial occlusion on smooth muscle
proliferation in the midzone and stem regions of the collateral circuit.



Specific Aim 3 - Determine the time dependence of smooth muscle proliferation
and changes in vessel cross-sectional area in the collateral circuit.
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Surgical Model
Femoral Artery Ligation
A femoral artery ligation surgery was performed to stimulate arteriogenesis in the
superficial adductor collaterals of the house hind limb. To obtain an aseptic environment,
surgical instruments and materials were autoclaved and the surgical field was disinfected
with Novalsan. Refer to the appendix for specific instruments and sterile pack contents.

Figure 4 On the left is a diagram of the proximal ligation site, on the right is the surgery setup for a
proximal ligation.

The mouse was then weighed and placed into an anesthesia induction chamber where it
was anesthetized with 5% isoflurane mixed with oxygen flowing at ~3 l/min. Once
anesthetized, anesthesia was maintained with 1-3% isoflurane mixed with oxygen
flowing at 0.5-1.0 l/min. An ear-hole punch was used for identification purposes (left ear,
right ear, both ears, no ears). The hair on the left hind limb was removed with clippers
and depilatory cream. The hind limb was then disinfected with Nolvasan and the animal
was then given a subcutaneous injection of buprenorphine (0.075mg/kg) for analgesia.
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Once the animal was moved to the heat pad, a surgical anesthetic plane was maintained
via a non-rebreathing nose-cone. Body temperature was maintained via rectal probe at
37°C and veterinary ointment was applied to the eyes to avoid desiccation.
A small incision was made in the middle medial aspect of the left thigh and extended up
to the abdominal wall. Once surgical exposure was maximized, a heat cautery was used
to resect the fat pad and the epigastric atrioventricular (a-v) pair. The femoral artery was
blunt dissected from the neurovascular bundle, in between the profunda femoris and
popliteal branches (See Figure 4). The femoral artery was tied off with a 6.0 silk suture
and the incision was closed using a 7.0 polypropylene suture. A contra-lateral sham
control was prepared by making a similar incision in the middle, medial aspect of the
right thigh and blunt dissecting the connective tissue. The incision on the sham limb was
also closed with a 7.0 polypropylene suture.
A second subcutaneous injection of buprenorphine (0.075mg/kg) was given for analgesia
post surgery. Once ambulatory, the animal was placed in a new cage with surgery
indicated on the cage card.
Ventricular Catheterization and Perfusion Fixation
Before the dissection, a vasodilator cocktail was prepared using heparin, adenosine, and
sodium nitroprusside, and heated to 37°C.
The mouse was then weighed and placed into an anesthesia induction chamber where it
was anesthetized and prepared as described above. The animal’s limbs where then taped
down to a heated bench cover and small incisions were made in the middle medial aspect
of both hind limbs to visualize the femoral a-v pair and ensure proper vascular profusion.
25

Methods
The skin was removed from the abdomen up to the top of the thoracic cavity. A 20 mL
syringe of the vasodilator cocktail was attached to a catheter and placed in the syringe
pump. An incision was made in the abdomen over the xiphoid process and hemostats
were clamped on the xiphoid process for handling of the thoracic wall prior to performing
a thoracotomy (see Figure 5).

Figure 5 Hemastats clamped on to exposed xiphoid process in
preparation for entering the thoracic cavity.

A small incision was made in the apex of the heart and a catheter was inserted into the
left ventricle and clamped in place with a vascular clamp. The right atrium was also cut
to allow drainage. Once catheterized, the vasculature was perfused with the vasodilator
cocktail at 4 mL/minute. Next, 15 mL of histochoice was perfused to fix the vasculature
in a dilated state (see Figure 6).
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Figure 6 Correct catheter placement in the left ventricle for vascular
perfusion.

The gracilis muscle and the profunda femoris artery were dissected from each hind limb
and fixed in histochoice overnight. After post fixation, the tissue was stored in PBS at
4°C.
Histology
Sample Preparation
The tissue samples were dehydrated and impregnated with paraffin wax with a Shandon
Excelsior ES tissue processor. Once processed, tissues were embedded in paraffin wax.
The gracilis muscles were cut perpendicular to the muscle striations (exposing a crosssection of the collaterals) and the profunda femoris artery was cut perpendicular to the
longitudinal axis to obtain a vascular cross-section. The tissues were placed with the
medial aspect of the sample facing down in the cassette (so that the middle of the arteries
would appear in the earlier sections). Once embedded, the tissue blocks were sectioned
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into 6μm sections using a Leica RM 2255 microtome. Tissue blocks were capped with
hot wax and left to dry until the next use to minimize protein oxidation.
Tissue Content Assessment
Before immunostaining, tissue morphology was assessed using a standard hematoxylin
and eosin stain (provided by Fisher Science). Once imaged, one can determine whether
the tissue cross section is the correct orientation, whether the tissue contains vessels (in
particular, gracilis collaterals or profunda femoris arteries), and whether these vessels
were properly perfused, dilated and fixed. Once tissue morphology was assessed, the
tissue blocks that contained pertinent vessels were marked for use in subsequent
immunostains.

Figure 7 Profunda femoris artery in the left hind limb 7 days after
femoral artery ligation (designated by black arrow).
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Immunohistochemistry
Immunohistochemistry was used to detect proliferating smooth muscle cells, with
peroxidase as the primary detection method. Tissues that contained pertinent vessels were
sectioned with at least two samples on each slide (allowing for a negative control). The
slides were placed into slide racks, and the paraffin was melted in an oven/incubator.
The samples were then rehydrated in xylene, dehydrant, and distilled water and placed in
an incubation chamber. Enzymatic antigen retrieval was performed with Promega
Proteinase K and permeablization with 0.1% Triton X-100. After blocking non-specific
protein binding with 1.5% donkey serum, proliferating smooth muscle cell nuclei were
labeled with a Ki-67 primary antibody. A donkey anti-rabbit biotinylated antibody was
used as the secondary detection method followed by the application of an avidin-biotin
complex. A DAB-peroxidase substrate was used to give the positive tissues a brown
precipitate. After dehydrating in dehydrant and xylene, samples were mounted and
imaged using a bright-field microscope (See appendix for specific reagents, dilutions and
incubation times).
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Figure 8 A gracilis collateral artery 7 days after femoral artery ligation stained
with Ki-67. Proliferating smooth muscle cells show a brown precipitate.

Immunofluorescence
Immunofluorescence was used to assess proliferating vs. non-proliferating smooth
muscle cells, as well as vessel lumen areas in the gracilis collaterals and profunda femoris
arteries. Tissues that contained pertinent vessels were sectioned, placed in slide racks,
and then in an oven/incubator to melt the paraffin. The samples were then rehydrated in
xylene, and dehydrant, and distilled water.
The slides were then taken out of the slide racks and placed into an incubator. Enzymatic
antigen retrieval was performed with Promega Proteinase K and permeablization with
0.1% Triton X-100. After blocking non-specific protein binding with 1.5% donkey
serum, proliferating smooth muscle cell nuclei were labeled by a Ki-67 primary antibody.
An Invitrogen Alexa Fluor® 594 donkey anti-rabbit IgG was used as a secondary
fluorescent detection method for the Ki-67. The sample was then stained with smooth
muscle α-actin that was labeled with a Invitrogen Zenon® Tricolor Mouse IgG2a
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Labeling Kit, allowing for the conjugation of a fluorescent complex to the α-actin
primary antibody. Once the samples were post-fixed in 10% formalin, a nuclear counterstain was performed with BBI. The slides were then mounted and examined under the
appropriate fluorescent light for imaging (see appendix for specific reagents, dilutions
and incubation times).

Figure 9 A Gracilis Collateral Artery 7 Days after a Femoral Artery Ligation. The collateral artery was
stained with Ki-67 (green), smooth muscle alpha actin (red), and BBI (blue).
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Morphology
Imaging
Three separate images were taken of each pertinent vessel in order to assess morphology.
One image showing Ki-67 positive cells, another image showing smooth muscle α-actin,
and a third showing cell nuclei (BBI) were all digitally captured. Once all samples were
imaged, morphological measurements were taken using ImageJ, a free scientific imaging
analysis software from the National Institutes of Health. An image of a 1mm micrometer
was also taken at various magnifications in order to calibrate the measurement features in
ImageJ.

Vessel Cross-Sectional Area
In order to make all measurements consistent, areas were taken from images of the
vessels stained with smooth muscle alpha actin because these images gave the best
contrast. This assumed that the endothelial cell layers of all the vessels were relatively the
same thickness since the measurement starts deep to the intimal layer. Although this
assumption may be inaccurate, measurements remained consistent among each other.
Images were converted into a binary form in to allow for a semi-automated tabulation of
luminal areas.
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Figure 10 Images of normally stained SM alpha actin (green) and the binary form of the image used to take
area measurements.

Once the areas were tabulated for each vessel, they were entered into a Microsoft Excel
spreadsheet under their respective tissue type and time point for further analysis.
Cell Nuclei Counting
Images of vessels displaying smooth muscle α-actin (green), Ki-67 (red) and BBI (blue)
were merged to determine which cell nuclei were smooth muscle nuclei, and which of
those smooth muscle cells were proliferating. Those nuclei immersed in green were
deemed smooth muscle cell nuclei. If these smooth muscle nuclei had red staining around
the edges or within the nuclei, it was deemed to be a proliferating nuclei cell. The amount
of normal and proliferating smooth muscle cells were then counted for quantification. An
example of smooth muscle phenotyping is shown in Figure 11.
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Figure 11 Phenotyping of vascular smooth muscle cells in a gracilis
collateral artery 3 days after femoral artery ligation. Non-proliferating
smooth muscle cells are designated by the white arrows. Proliferating
smooth muscle cells are designated by yellow arrows.

Data Analysis
Once the experimental data (vessel cross-sectional areas and vascular smooth muscle cell
quantity) was gathered from each sample, a statistical analysis was performed using
Microsoft Excel. A two-sample t-test (assuming unequal variances) was done, comparing
data from the non-ligated and ligated samples for each time point (e.g. non-ligated vs.
ligated gracilis cross-sectional areas for day 3, 7, 14). Two-sample t-tests were also used
to compare the data from each time point for the profunda femoris versus the gracilis
collaterals. Regression analysis and analysis of variance (ANOVA) was used to compare
individual sets of data to their counterparts at the different time points (e.g. day 3 vs. day
7 vs. day 14 ligated left gracilis cross-sectional areas). Statistical data was presented in
mean ± standard error of the mean and statistical significance was determined by p < 0.05.
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Vessel Cross-Sectional Area
Cross-sectional area measurements were taken of the medial luminal area (this assumes
that the endothelial cell layers of all the vessels are relatively the same thickness since the
measurement starts at the media layer) for each vessel. Although vessel size appears to
markedly increase as the post ligation period increased, a significant difference between
the ligated and non-ligated areas was only seen at the day 7 and day 14 time points. A
one way ANOVA for independent samples shows that the cross-sectional areas of the
ligated gracilis collaterals for day 14 are significantly different than that of day 3 and day
7 (see Figure 13).

Figure 12 Progression of gracilis collateral enlargement over a two week period. Images chosen where
those closest to the average in all groups. Vessel cross-sections were stained with smooth muscle α-actin
(green).
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Figure 13 Average gracilis collateral cross-sectional areas in ligated and non-ligated c57 hind limbs areas
at 3, 7, and 14 days after femoral artery ligation. At day 7 and day 14 the areas are significantly different
with p values of 0.0352( denoted by ▲) and 0.0007 (denoted by )respectively. A one-way ANOVA
shows that day 14 ligated CSA is significantly different from day 3 and day 7(denoted by ■).

The profunda femoris (muscular branch artery) showed a trend of increased crosssectional area as the post ligation time increased. However, although there was a trend of
growth throughout the examined time periods, the cross-sectional areas of the ligated
versus the contra lateral control was not significantly different for any time points (see
Figure 15).

Figure 14 An average sham (day 0) profunda femoris artery (left) and a profunda
femoris artery 14 days after a femoral artery ligation (right). Images chosen where those
closest to the average in both groups. Vessel cross-sections were stained with smooth
muscle α-actin (green).
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Figure 15 Average profunda femoris cross-sectional areas in ligated and non-ligated c57 hind limbs at 3, 7,
and 14 days after femoral artery ligation. Although there was an increasing trend in the average area of the
vessels in the ligated legs, no significant difference was seen between the ligated and contra lateral control.

When comparing the cross-sectional areas of the ligated gracilis collateral and profunda
femoris arteries it appears that the gracilis collaterals generally approach the relative size
of the profunda femoris arteries. A t-test shows that the profunda femoris and gracilis
collateral cross-sectional areas are significantly different in day 3. Although the
difference between the averages of the gracilis collateral and profunda femoris arteries is
larger in day 7 than it is in day 3, a t-test showed that the day 7 averages were not
significantly different. Figure 6 shows that the cross-sectional area of the gracilis
collaterals approaches that of the profunda femoris over the two week period.
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Figure 16 Progression of gracilis collaterals (top row) and profunda femoris arteries
(bottom row) from day 0 (left column) to day 14 (right column). Images used were
those with areas closest to the average. Vessel cross-sections were stained with
smooth muscle α-actin (green).

Figure 17 The average gracilis collateral vs. profunda femoris cross-sectional areas in ischemic c57 hind
limbs at 3, 7, and 14 days after femoral artery ligation. A t-test with a p-value of 0.002 (denoted by )
shows that the areas of the two arteries are significantly different at day 3.
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Vascular Smooth Muscle Cell Quantification
Total Smooth Muscle Cell Count
The total number of vascular smooth muscle cells (VSMCs) present in each vessel was
tabulated. In the gracilis collaterals, there was an increasing trend in the average number
of VSMCs in the ligated samples. However, only days 3 and day 14 showed a significant
difference between the ligated and contra lateral control. Although a one-way ANOVA
gave a p-value of 0.0411, the difference between the averages in the ligated gracilis
collaterals at day 3, day 7, and day 14 were deemed non-significant.

Figure 18 The average number of vascular smooth muscle cells in the gracilis collaterals in ligated and
non-ligated hind limbs. The average number of smooth muscle cells was significantly different at day 3 and
day 14, with p-values of 0.0128 (denoted by ▲) and 0.0002 (denoted by ), respectively.
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As for the profunda femoris arteries, there was little variation between the ligated and
non-ligated groups. None of the time points showed a significant difference when
comparing the ligated with the non-ligated hind limb (see Figure 19).

Figure 19 The average number of vascular smooth muscle cells in the profunda femoris arteries in ligated
and non-ligated hind limbs. None of the time points showed a significant difference when comparing the
ligated and non-ligated data.

When comparing the quantity of VSMCs in gracilis collaterals and profunda femoris
arteries, all time points showed a significant difference. Although all p-values were under
0.05, the day 3 and day 7 time points were more significantly different than that of day 14
(see Figure 20).
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Figure 20 The average number of VSMCs in the gracilis collaterals and profunda femoris arteries in the
ligated c57 hind limbs. Days 3 and 7 gave p-values less than 0.01 (0.0032 and 0.0098 respectively, denoted
by ) and day 14 gave a p-value less than 0.05 (p=0.01, denoted by ▲).

Smooth Muscle Cell Phenotype
The only samples that stained positive for Ki-67 were the gracilis collaterals at day 3 and
day 7 following a femoral artery ligation. This signifies that smooth muscle cells were
proliferating at day 3 and day 7, but not day 14. There was an average of 1.6 and 2.5
proliferating VSMCs at day 3 and day 7 respectively. A t-test showed that the amount of
proliferating VSMCs present at day 3 and day 7 are significantly different than those
found at day 0 (sham) and day 14. The line graph shown in Figure 22, shows the
progression of the proliferating VSMCs over the two week period.
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Figure 21 Progression of the gracilis collaterals over the two week post-ligation period. Vessels chosen
were those that had the closest areas and amount of VSMCs to the averages in each group. Each vessel was
stained with smooth muscle α-actin (green), the Ki-67 proliferation marker (red), and BBI for the nuclei
(blue).
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Figure 22 Average number of proliferating smooth muscle cells in ligated gracilis collateral arteries. A ttest showed that days 3 and 7 were significantly different from day 0 and day 14 with a p-value less than
0.005 (p = 0.0003, 0.0033 for day 3 and day 7 respectively).
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Time Dependence of Smooth Muscle Cell Phenotype
The gracilis collaterals experienced arteriogenesis following a femoral artery ligation in
the C57 mouse hind limb, Figure 21. Evidence of this was supported by the fact that the
smooth muscle cells that were positive for Ki-67 at 3 and 7 days and collaterals
significantly enlarge over the two week period following the ligation. Although smooth
muscle cells were quantified, we mainly wanted to show that proliferation was observed
at day 3 and day 7, but not at day 0 and day 14. To obtain a more accurate quantification
in the future, imaging exposure times, incubations periods, and procedural conditions
must remain consistent in order to use implications, such as fluorescent intensity, as an
indication of quantity.
Since the Ki-67 protein is expressed during all active phases of the cell cycle and the
rapid disappearance of the Ki-67 antigen is associated with a non-proliferative (inactive)
state of any part of the cell cycle [27], we can also postulate that SMCs positive for Ki-67
are proliferating, or in a synthetic state. Although there was a trend of more proliferation
at day 7, a one-way ANOVA shows that the average amounts of proliferating VSMCs
present at days 3 and 7 are not significantly different.
These findings were somewhat consistent with previous work. The first positive Ki-67
reaction (i.e. proliferating cells) in the vessel wall of the growing collaterals in New
Zealand white rabbits was found 24 hours after the occlusion in the mid-zone of the
collaterals of the quadriceps [28]. The Ki-67 reaction increased up to day 3, however
proliferation diminished in the collaterals at days 7 and 21 [28].
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Previous work in mice was also used to distinguish the different phases of remodeling
during arteriogenesis. The first, proliferative phase of arteriogenesis occurs 1-3 days after
occlusion, and is characterized by a maximal mitotic activity in the endothelial cells,
SMCs, and fibroblasts [28]. The next stage is the synthetic/growth phase (3-14 days) that
is characterized by reduced mitosis and initiation of synthetic and proteolytic activity in
SMCs [28]. During this time the internal elastic lamina is digested and fragmented by the
elastolytic enzymes to facilitate positive remodeling by the SMCs [28]. Although the
previous work was done in New Zealand white rabbits, the time course is similar to that
of our study.
Previous work also characterized the proliferation phase as 1-3 days after occlusion [29].
Three days after femoral occlusion in the mouse hind limb, remodeling is characterized
by swollen endothelium, disrupted elastic lamina, mitotic phenotypes in both smooth
muscle and endothelial cells (evidenced by endothelial and smooth muscle cells taking up
BrdU and Ki-67 labeling) [6]. The period from 3 days to 2 weeks is defined as the
synthetic phase and is characterized by high proliferation activity at the beginning of the
phase, followed by the first recovery of blood flow to the ischemic limb after 7 days [29].
The vessel's ultrastructure returned to normal 7 to 14 days after occlusion, and the BrdU
and Ki-67 labeling decreased [6]. Then, after 10 to 14 days proliferation activity
diminishes and SMCs gradually return to the contractile phenotype [29].
Although my results were similar to previous work, this study only measured
proliferation in the SMCs, so another cogitation to be considered about this study is the
distinction between a proliferating and a synthetic smooth muscle cell. Since only
proliferating smooth muscle cells were assessed, we want to know what allotment of
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those cells were in a "synthetic" state as well. Smooth muscle cells dynamically exhibit
distinct contractile and synthetic phenotypes with unique morphological, biochemical,
functional, and gene expression characteristics [24]. The plasticity of the length-tension
properties and the organization of contractile filaments in smooth muscle further extends
the functional diversity of SMCs [24]. These observations tell us that there is a full
spectrum of SMC function, dictated by phenotypic and mechanical plasticity, that is
controlled by molecular mechanisms [24].
Although SMCs are on a plastic continuum, cells in the contractile state are deemed nonproliferative, evidenced by the fact that this phenotype is that of a differentiated cell. This
is not to say that contractile smooth muscle cells have zero proliferation, but that there is
a minimal rate of proliferating and a balance in the production and degradation of
proteins [30]. According to Scholz et al., although proliferation appears to peak at day 3,
it is present for up to three weeks, which encompasses the synthetic activity period in the
SMC (3 to 14 days) [28]. From this, we can postulate that Ki-67 positive smooth muscle
cells from day 3 to day 14 is of a synthetic nature.
Impact of Location on the Collateral Circuit
Although we saw proliferation in the gracilis collaterals, the mid-zone of the collateral
circuit, there was no proliferation seen in the profunda femoris (muscular branch)
arteries, the stem region of the collateral circuit, at any of the time points. However,
following the femoral artery ligation, the average cross-sectional area of the profunda
femoris experienced an increasing trend over the two week period. While an increasing
trend was seen, a t-test on all three time points showed that none of the average areas
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were significantly larger than the non-ligated samples. A one-way ANOVA also
demonstrated that the average areas at the post ligation time points were not significantly
different, nor were the non-ligated time points. Although no significant difference was
seen in this study, previous work does show a significant difference at certain time points.
Despite observing no proliferation or a significant increase in profunda femoris crosssectional area, it has been well documented that an arterial occlusion can lead to impaired
vasoactivity in the stem region of the collateral circuit. Proliferating smooth muscle cells
seen after an occlusion could explain abnormal functional dilation in the gracilis
collaterals. However, we found no proliferating SMCs in the profunda at any time after
the occlusion, leading us to believe that the impaired vasodilation may be caused by other
changes in smooth muscle phenotype or may not be smooth muscle dependent.
Two previous studies on the impact of vascular occlusion on vascular reactivity through
femoral artery ligation showed cross-sectional area measurements that were inconsistent
with those of this study. The vessel diameter measurements for the previous studies were
taken via in vivo intravital microscopy and because the vessel measurements for this
study were taken via histological analysis, there are expected discrepancies between the
two sets of data.
Our group measured cross-sectional areas (assuming a perfectly cylindrical vessel) 3 days
after the same proximal femoral artery ligation and saw no significant difference between
vessel diameters of the ligated and non-ligated profunda femoris arteries. Although the
areas tabulated from this study (ligated profunda CSA ≈ 2,551 µm2, non-ligated profunda
CSA ≈ 1654 µm2) and my own (L = 1643 µm2, NL = 2176 µm2) are slightly different,
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the overall data for this time point was consistent between the two. Our group also
measured two sets of day 7 cross-sectional areas, which yielded different results from the
measurements of this study. The first set of cross-sectional area measurements of the
ligated profunda femoris (≈ 3525 µm2) was significantly larger (p-value < 0.05) than that
of the non-ligated profunda femoris (≈ 1978 µm2) 7 days post occlusion. The second set
of measurements also yielded a significant difference (p-value < 0.01) in the crosssectional areas of the ligated (≈ 7853 µm2) and non-ligated (≈ 1963 µm2) profunda
femoris arteries. Although the measurements are within reasonable range of my own (L =
1789 µm2, NL = 1568 µm2), there was a statistical difference present that did not occur in
this study. Previous measurements by our group also showed a significant difference (pvalue < 0.01) between the ligated (≈ 6361 µm2) and the non-ligated (≈ 2375 µm2)
profunda femoris arteries 14 days after occlusion. Similar to the day 7 study, the nonligated profunda femoris (= 1664 µm2) from this study is within range, but the ligated
profunda femoris (= 2239 µm2) was much smaller and there was no significant difference
between the two.
There are many physiological and experimental factors that could have attributed to the
substantial differences seen in the ligated profunda femoris measurements, especially in
the day 7 and day 14 studies. The main source of inconsistencies was most likely the
different methods of vessel measurement. Intravital microscopy measurements from the
previous two studies were taken in vivo when the vasculature was in a resting state. In
this study, the vasculature was perfused with a vasodilator and immediately perfused with
a fixative to achieve a maximal resting diameter. However, ventricular catheterization is a
delicate procedure. At times, only the arterial side would perfuse or the vasodilator would
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barely perfuse the vasculature at all (due to improper catheter placement, puncture of the
ventricular septum, clotting, etc.). Because of this, not all vessels were fixed in a fully
dilated state. Also, to examine samples histologically, the tissues must be processed, a
procedure that tends to substantially shrink the tissues.
Aside from the different methods of taking vessel measurements, another source of error
could have originated from the ligation procedure. Although each surgeon followed the
same procedure for the proximal femoral artery ligation, inconsistencies can still occur.
For instance, if there were branch points proximal to the ligature and distal to the
profunda, there would be a reduced shear on the profunda, which may have had an effect
on the results obtained.
Although different results were obtained from this study and previous similar studies, the
overall trend shows an enlargement of the profunda post occlusion. This is expected
because of the increased blood flow in the profunda femoris when the femoral artery is
occluded. Although the profunda increases in diameter, impaired functional vasodilation
was only seen in one of the two studies on the effects of vascular occlusion. The other
study showed that the ligated and non-ligated profundas dilated relatively the same
percent when stimulated.
The next logical step would be to take the same intravital measurements at 3, 7 and 14
days post ligation to confirm the presence of a functional vasodilation impairment. If no
impairment is observed, this would support the hypothesis that smooth muscle
proliferation is necessary to induce impaired vasodilation. Since the vessel did not
contain proliferative cells, if impaired dilation is observed, it is possible that the
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impairment was due not to proliferation, but an acute mechanoadaptation, which may
have occurred to cause the profunda to enlarge following the occlusion. In response to
prolonged constriction, VSMCs undergo a mechanoadaptation process involving "length
autoregulation" that would be energetically favorable for maintenance of a reduced vessel
diameter [31]. This process involves cellular repositioning of the VSMCs in the presence
of the maintained constriction[31]. Although this phenomenon has mostly been witnessed
in vessels exposed to prolonged vasoconstriction, studies have shown that prolonged
vasodilation can also cause acute outward remodeling [32]. Although there is no evidence
that the SMCs in the profunda experienced this acute mechanoadaptation following the
ligation, this could explain why the vessel enlarged over the two week period in all three
studies, without proliferation, and may explain any confirmed impairment in functional
vasodilation. While the smooth muscle cells do not change phenotypes during this
mechanoadaptation, it is possible that a transient reduction in smooth muscle function
could have occurred due to the reconstitution of the extracellular matrix and the
repositioning of the smooth muscle cells.
To test this hypothesis we would measure vascular reactivity to endothelial and smooth
muscle dependent agents using intravital microscopy. This would initially involve the
same surgical procedure as the previous experiments in which a ligation surgery would
be performed on at least six mice for each time point (day 3, day 7, day 14). At each time
point the mice would undergo a superfusion procedure in which smooth muscle and
endothelial dependent dilators (e.g. sodium nitroprusside and acetylcholine) would be
placed over the profunda while diameter measurements are taken simultaneously via
intravital microscopy. If the profunda does not respond to endothelial or smooth muscle
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dependent dilators, then the aforementioned hypothesis of a transient reduction in smooth
muscle function due to a mechanoadaption would be supported. If the profunda only
responds to smooth muscle and not endothelial dependent dilators, then this would
support the hypothesis that the impairment is endothelial dependent.

Although impaired vascular function is not likely a result of smooth muscle cell
proliferation in the profunda, as mentioned above, it is possible that SMCs are the cause
of vascular impairment in the gracilis collaterals. The gracilis collaterals enlarged over
the two week period following a femoral artery ligation. A t-test shows that the average
cross-sectional areas from day 7 (= 805 µm2) and day 14 (= 2237 µm2) are significantly
different from that of day 0 averages (= 417 µm2), with p-values of 0.0352 and 0.0007
respectively. Also, a one-way ANOVA showed that the average CSA at day 14 was
significantly different from that at days 3 and 7. This data is consistent with many other
studies in which we see significant collateral growth over a two week time period
following an upstream arterial occlusion.
Since SMCs were proliferating at day 3 and day 7 following a ligation in the gracilis
collaterals, the next logical experimental step would be to examine vascular function in
this region of the collateral circuit following an occlusion. This experiment would require
the use of a multiphoton fluorescence microscope, as the gracilis collaterals are too deep
to examine via traditional intravital microscopy. At each time point following the ligation
surgeries (day 3, day 7, day 14), fluoropores would be injected into the vasculature in
order to make the collaterals visible via fluorescent microscopy. Once visible, functional
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measurements can be taken following the application of SNP and acetylcholine to
determine the functionality of both endothelial and smooth muscle cells. If there is little
functional response to SNP and these responses parallel the same time course as smooth
muscle proliferation, this would strongly suggest that vascular impairment is smooth
muscle dependent in the gracilis collaterals following a ligation.

Conclusions
At days 3 and 7 following a femoral artery ligation, we observed proliferating smooth
muscle cells in the gracilis collaterals as well as significant collateral vessel growth over
a two week period. This study correlated well with previous studies in that proliferation
followed a similar time course, and significant vessel growth was observed. As
mentioned above, the next logical step would be to determine if the time course of
proliferation parallels with functional impairment in the gracilis collaterals. If there is a
parallel, then this would strongly suggest that the impairment in the gracilis collaterals is
due to smooth muscle dysfunction during their phenotypic transition.
Following the same ligation we did not observe any proliferation in the profunda femoris
and although there was an increasing trend in vessel size over the two week period, none
of the averages were significantly different. These results differed from those of previous
studies performed within the lab group. The previous studies also differed in that one
study observed impairment and one did not. For this reason, the next step should be to
make functional measurements again to determine if there is impairment in the profunda
after a ligation. If there is no impairment then my results would make sense, since there is
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no SMC proliferation. If there is impairment, then we know that smooth muscle cell
proliferation is not the cause, and further tests need to be done to find the cause of this
vascular dysfunction.
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Protocols

Femoral Artery Ligation Protocol
Materials
Sterilize- autoclave or flash autoclave
____1.
____2.
____3.
____4.
____5.

forceps (2)
fine forceps (2)
ultrafine forceps (1)
fine scissors (1)
microscissors spring loaded (1)

Pre-sterilize in autoclave
____6.
____7.
____8.
____9.

cotton gauze (2)
cotton swabs (12)
6.0 silk suture (2 x 1-inch)
needle holder (1)

Obtained in surgery suite
____10.
____11.
____12.
____13.
____14.
____15.
____16.
____17.
____18.
____19.
____20.
____21.

sterile Petri dish w/ sterile saline
sterile gloves
sterile 7.0 prolene suture
heat-cautery
FST heat pad w/ rectal probe
heat pad
recovery bin & weigh boat
depilatory cream
non-sterile cotton swabs
non-sterile cotton gauze
isolation mask & cap
analgesic (Buprenorphine)

Surgery preparation
____22.

Spray surgery area with Nolvasan
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____23.
____24.
____25.
____26.
____27.
____28.
____29.
____30.
____31.
____32.
____33.
____34.

Weigh animal in weight boat
Place animal in anesthesia box
Open the oxygen cylinder and set anesthesia-machine flow meter to ~3 l·min-1
Anesthetize animal w/ 5% isoflurane
Affix non-rebreathing circuit to bench-top with tape
Reduce flow rate to 0.5-1.0 l·min-1 and the isoflurane to 1-3%
Apply ear tag high on left ear
Lay animal supine with nose in nose-cone
Shave hair on the right hindlimb & lower abdomen with clippers
Remove excess hair with depilatory cream
Spray right hindlimb with Nolvasan
Return animal to anesthesia box

____35.
____36.
____37.
____38.
____39.
____40.

Apply 4x4 gauze sponge to heat pad to protect animal from excessive heat
Affix non-rebreathing circuit to surgery table w/ chemistry clamp
Lay animal supine on circulating heat pad w/ nose in nose-cone
Insert rectal probe and set thermo-controller to 37°C
Apply veterinary ointment to eyes to avoid drying during procedure
Apply veterinary ointment to anus and place rectal probe ~1cm into anus to
monitor core-body temperature

Surgery
____41.
____42.
____43.
____44.
____45.
____46.
____47.
____48.
____49.
____50.
____51.

Make a small incision on the middle, medial aspect of the left thigh
Extend the incision up to the abdominal wall
Blunt dissect the subcutaneous connective tissue to maximize surgical
exposure
Use cautery to remove fat pad overlying femoral a-v pair & cauterize
epigastric av-pair
Blunt dissect the femoral artery from the neurovascular bundle just
downstream from the deep femoral branch
Tie off the femoral artery & vein with 6.0 silk suture, just downstream to the
deep femoral branch
Use 6.0 polypropylene suture to close the skin
Make a small incision on the middle, medial aspect of the right thing
Extend the incision up to the abdominal wall
Blunt dissect the subcutaneous connective tissue to maximize surgical
exposure
Use 6.0 polypropylene suture to close the skin
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Post-Surgical
____52.
____53.
____54.
____55.

Give the animal an subcutaneous injection of buprenorphine (0.075mg/kg)
Place the animal in the recovery bin, on a blue bench cover, above a heat pad
and allow to recover
Turn flow meter down to 0, turn off isoflurane, and close the oxygen cylinder
Indicate surgery on cage card

Perfusion Fixation Protocol
Materials
Non-Sterilize Dissection Instruments
____56.
____57.
____58.
____59.
____60.
____61.
____62.

forceps (2)
fine forceps (2)
Bone Scissors(1)
Skin Scissors (1)
Dissection Scissors (1)
Hemostats(1)
Vascular clamp (1)

Obtained in surgery suite
____63.
____64.
____65.
____66.
____67.
____68.
____69.
____70.

Tape
10mL Syringes (2)
Bench cover
Heating pad
Catheter
Avertin Anesthetic
Non-sterile saline
Cotton swab

Vasodilator Cocktail Preparation
____71.
____72.
____73.
____74.
____75.
____76.
____77.
____78.

Turn on water bath to 37ºC
400 µL heparin
1mL SNP(orange)
600µL Adenosine(clear)
38mL PBS solution
Thaw SNP and Adenosine
Add heparin, SNP, Adenosine, and PBS solution together in a 50mL conical
Place vasodilator cocktail in water bath
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____79.

Prepare 15mL of histochoice in a 50mL conical and place in water bath

Procedure Preparation
____80.
____81.

Weigh animal and draw up appropriate dose of Avertin anesthetic
(.15mL/10g)
Obtain saline filled beaker, cotton swab, and instruments

Fixation
____82.
____83.
____84.
____85.
____86.
____87.
____88.
____89.
____90.
____91.
____92.
____93.
____94.
____95.

Anesthize mouse with Avertin
Heat up heat pad in microwave and wrap with bench cover when warm
Remove hindlimb hair on both legs by shaving
Tape animal down to heated bench cover
Separate skin from muscle from the abdomen to the top of the thoracic cavity
Fill 10mL syringe with warm Vaso D
Cut through abomen close to diaphragm
Quickly cut through the ribs and diaphragm to open chest cavity and clamp
back with hemostats
Cut away excess tissue around the heart
Make a small incision in the apex of the heart
Insert catheter and clamp with vascular clamp and cut right ventricle
Inject Vaso D solution into animal approximately 20mL
Inject 12mL of histochoice
Dissect the muscular branch and gracilis muscle preserve in histochoice

Ki-67 Immunohistochemistry Protocol

Materials
Histology Components
____96.
____97.
____98.
____99.
____100.
____101.
____102.
____103.

Microscope slides
Staining dishes (4)
Incubating chamber
Hydrophobic pen
Microscope slide rack
Hemostats
Mounting Medium
Cover slips
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Reagents Checklist (See protocol appendix for reagent preparation)
____104.
____105.
____106.
____107.
____108.
____109.
____110.
____111.
____112.
____113.
____114.
____115.
____116.

Xylene
100% EtoH
95% EtoH
Distilled Water
Phosphate Buffered Saline
Promega Proteinase K*
PBST*
Hydrogen Peroxide (H2O2)
Blocking Serum*
Ki-67 primary antibody*
Biotinylated secondary antibody*
AB Enzyme*
Peroxidase Substrate*

Sample Preparation and Rehydration
____117. Section desired number of blocks on a desired number of slides
____118. Place slides in a slide rack and put in oven/incubator and turn dial to “7” and
remove when wax has melted
____119. While was is melting, prepare four staining dishes with the following
reagents: xylene, 100% EtoH, 95% EtoH, and distilled H20.
____120. When wax is melted, place slide rack in xylene dish for 10 minutes.
____121. Place slides in 100% EtoH for 2 minutes (x2).
____122. Place slides in 95% EtoH for 2 minutes.
____123. Place slides in distilled for 2 minutes.
Staining Procedure
____124. Remove slides one by one from distilled water, circle samples with
hydrophobic pen, and place in incubator.
____125. Incubate samples in Proteinase K working solution for 10 minutes.
____126. Wash with PBS for 5 minutes.
____127. Incubate in PBST for 15 minutes.
____128. Wash with PBS for 5 minutes.
____129. Block non-specific peroxidase binding with H2O2 for 10 minutes.
____130. Wash with distilled H2O for 5 minutes.
____131. Block samples with blocking serum for 30 minutes.
____132. Apply Ki-67 primary antibody to one sample on the slide (leaving only
blocking serum on the other sample for a positive control) and incubate over
night at 4°C.
____133. Wash with PBS for 5 minutes
____134. Incubate in biotinylated secondary antibody for 30 minutes
____135. Immediately after applying secondary antibody, prepare AB enzyme.
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____136.
____137.
____138.
____139.
____140.
____141.
____142.
____143.
____144.

Wash with PBS for 5 minutes
Apply AB enzyme and incubate for 30 minutes
Wash with PBS for 5 minutes
Apply peroxidase substrate and incubate for 5 minutes
Wash slides in distilled H2O
Dip slides in 95% EtoH for 10 seconds (x2)
Dip slides in 100% EtoH for 10 seconds (x2)
Dip slides in xylene for 10 seconds (x3)
Mount slides with mounting medium and allow them to dry over night.

Reagent Preparation
All working solutions can be stored @ 4°C for 2-3 weeks unless otherwise specified.
Proteinase K working solution:
Use Promega Proteinase K (Specific Activity: 30u/mg) and dilute 1:500 in PBS.

Phosphate Buffered Saline /w Triton X-100(PBST):
Use 1% Triton x-100 in PBS (i.e. .05mL of Triton
X-100 in 5mL of PBS)
Blocking Serum:
Use the same blocking serum in which your
secondary antibody was raised (i.e. if you’re using a
donkey anti-rabbit secondary antibody, use
donkey blocking serum). Add 75μL of blocking
serum stock to 5 mL of PBST for blocking serum
working solution.
Ki-67 Primary antibody:
Use Abcam Ki-67 rabbit polyclonal primary
antibody (ab15580), use a 1:200 dilution in
blocking serum working solution (i.e. 10μL of
primary antibody stock in 2mL of blocking serum
working solution).
Biotinylated Secondary antibody:
Since primary antibody is a rabbit polyclonal,
use an “anti-rabbit” secondary antibody (i.e.
donkey anti-rabbit). For working solution add 75μL
of blocking serum stock and 25μL of secondary
antibody stock to 5mL of PBS.
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AB Enzyme:
Use Vector Labs Vectastain Elite ABC reagent. For
working solution, add two drops of Reagent A, and
two drops of Reagent B to 5mL of PBS, mix
immediately and allow ABC reagent to stand for
about 30 minutes before use.
Peroxidase Substrate:
Prepare substrate before use every time, do not
store. For working solution add one drop of
peroxidase substrate, one drop of DAB chromagen,
and 5 drops of 10x substrate buffer to 1.6mL of
distilled water.
Smooth Muscle Cell Phenotyping Immunofluorescence Protocol
Materials
Histology Components
____145.
____146.
____147.
____148.
____149.
____150.
____151.
____152.

Microscope slides
Staining dishes (4)
Incubating chamber
Hydrophobic pen
Microscope slide rack
Aluminum Foil
Hemostats
Cover slips

Reagents Checklist (See Appendix for reagent preparation)
____153.
____154.
____155.
____156.
____157.
____158.
____159.
____160.
____161.
____162.
____163.
____164.
____165.
____166.

Xylene
100% EtoH
95% EtoH
Distilled Water
Phosphate Buffered Saline
Promega Proteinase K*
PBST*
Blocking Serum*
Ki-67 primary antibody*
Ki-67 fluorescent anti-rabbit secondary antibody*
SM α-actin fluorescent complex**
10% Formalin
BBI*
Fluorescent mounting medium
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Sample Preparation and Rehydration
____167. Section desired number of blocks on a desired number of slides
____168. Place slides in a slide rack and put in oven/incubator and turn dial to “7” and
remove when wax has melted
____169. While wax is melting, prepare four staining dishes with the following
reagents: xylene, 100% EtoH, 95% EtoH, and distilled H20.
____170. When wax is melted, place slide rack in xylene dish for 10 minutes.
____171. Place slides in 100% EtoH for 2 minutes (x2).
____172. Place slides in 95% EtoH for 2 minutes.
____173. Place slides in distilled for 2 minutes.
Staining Procedure
____174. Remove slides one by one from distilled water, circle samples with
hydrophobic pen, and place in incubator.
____175. Incubate samples in Proteinase K working solution for 10 minutes.
____176. Wash with PBS for 5 minutes.
____177. Incubate in PBST for 15 minutes.
____178. Wash with PBS for 5 minutes.
____179. Block samples with blocking serum for 30 minutes.
____180. Incubate in Ki-67 primary antibody over night at 4°C
____181. Wash with PBS for 5 minutes
____182. Cover incubator in aluminum foil to protect from the light for rest of
procedure
____183. Incubate in Ki-67 fluorescent anti-rabbit secondary antibody for 90 minutes
____184. Wash with PBST for 5 minutes
____185. Incubate in SM α-actin fluorescent complex for 45 minutes
____186. Wash with PBST for 10 minutes (x3)
____187. Wash with PBS for 5 minutes (x2)
____188. Fix samples with 10% formalin for 15 minutes
____189. Wash slides with PBS
____190. Incubate samples in BBI for 10 minutes
____191. Wash slides with PBS
____192. Mount slides with fluorescent mounting medium, protect them from light, and
allow them to dry over night
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Reagent Preparation
*All working solutions can be stored @ 4°C for 2-3 weeks unless otherwise specified.
**SM α-actin fluorescent complex needs to be used within 30 minutes of preparing it.
Proteinase K working solution:
Use Promega Proteinase K (Specific Activity: 30u/mg) and dilute 1:500 in PBS.
Phosphate Buffered Saline /w Triton X-100 (PBST):
Use 0.1% Triton x-100 in PBS (i.e. .05mL of Triton X-100 in 50mL of PBS)
Blocking Serum:
Use the same blocking serum in which your
secondary antibody was raised (i.e. if you’re using a
donkey anti-rabbit secondary antibody, use
donkey blocking serum). Add 75μL of blocking
serum stock to 5 mL of PBST for blocking serum
working solution.
Ki-67 Primary antibody:
Use Abcam Ki-67 rabbit polyclonal primary
antibody (ab15580, Lot #GR21314-1) , use a 1:200
dilution in blocking serum working solution (i.e.
10μL of primary antibody stock in 2mL of blocking
serum working solution).
Ki-67 fluorescent anti-rabbit secondary antibody:
Since primary antibody is a rabbit polyclonal,
use an “anti-rabbit” secondary antibody (i.e.
donkey anti-rabbit). For working solution dilute
anti-rabbit fluorescent secondary antibody 1:1000 in
blocking serum working solution (i.e. add 5μL of
fluorescent 2° ab to 5mL of donkey serum in
PBST).
SM α-actin fluorescent complex:
**Complex must be used with in 30 minutes of preparing it. For 10 slides, add 10μL of
sm α-actin to 0.5mL of PBS. Add 5μL of the desired color of the Zenon labeling
component, shake, and incubate for 5 minutes. Add 5μL of Zenon blocking serum, shake
and incubate for 5 minutes. Add .5mL of blocking serum working solution. Use within 30
minutes.
BBI fluorescent nuclear stain:
Dilute BBI stock 1:1000 in 18mΩ H2O (i.e. 10μL of BBI in 10mL of 18mΩ H2O).
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Vessel Morphology and Phenotype Raw Data
Day 3
Ligated Left
Gracilis

Block Number
11-222 a
11-222 b
11-230 a
11-230 b
11-234 a
11-234 b
11-238 a
11-238 b
11-242
Average
Standard
Deviation
Standard Error

Proliferating
Cross-Sectional Smooth Muscle
Smooth Muscle
2
Area (μm )
Cell Count
Cell Count
486.4
1
2
441.2
2
5
735.3
0
3
1928.9
2
6
697.1
3
3
630.4
2
4
867.2
2
3
257.9
1
2
455.2
1
2
722.1777778
1.555555556
3.333333333
488.3396456
162.7798819

0.836660027
0.278886676

0.836660027
0.278886676

Ligated Left
Muscular Branch

Block Number
11-223
11-227
11-231
11-235
11-239
11-243
Average
Standard
Deviation
Standard Error

Proliferating
Cross-Sectional Smooth Muscle
Area (μm2)
Cell Count
1735.2
2008.1
1965.8
1750.1
639.4
1764.1
1643.783333
505.8346742
206.506141
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Smooth Muscle
Cell Count
0
0
0
0
0
0
0

8
12
6
10
4
9
8.166666667

0
0

2.857738033
1.166666667
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Non-Ligated
Right Gracilis

Block Number
11-178
11-224
11-228
11-232
11-244
Average
Standard
Deviation
Standard Error

Proliferating
Cross-Sectional Smooth Muscle
Area (μm2)
Cell Count
553.7
259.5
583.8
224.2
407.6
405.76
164.2740789
73.46560147

Smooth Muscle
Cell Count
0
0
0
0
0
0

1
2
3
1
2
1.8

0

0.836660027
0.374165739

Non-Ligated
Right Muscular
Branch

Block Number
11-225
11-229
11-233
11-237
11-241
11-245
Average
Standard
Deviation
Standard Error

Proliferating
Cross-Sectional Smooth Muscle
Area (μm2)
Cell Count
4797.7
3113.2
538.8
902.2
2780.3
925.7
2176.316667
1672.308165
682.7169494
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Smooth Muscle
Cell Count
0
0
0
0
0
0
0

14
8
9
6
11
6
9

0
0

3.098386677
1.264911064
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Day 7
Ligated Left
Gracilis

Block Number
11-198 a
11-198 b
11-210 a
11-210 b
11-218 a
11-218 b
Average
Standard
Deviation
Standard Error

Proliferating
Cross-Sectional Smooth Muscle
Smooth Muscle Cell
2
Area (μm )
Cell Count
Count
747.8
3
3
680.6
3
6
1207.8
3
3
980
0
1
669.5
4
6
545.7
2
3
805.2333333
2.5
3.666666667
243.8099478
99.5349944

1.378404875
0.562731434

1.966384161
0.802772972

Ligated Left
Muscular Branch

Block Number
11-199
11-203
11-207
11-215
Average
Standard
Deviation
Standard Error

Proliferating
Cross-Sectional Smooth Muscle
Area (μm2)
Cell Count
1403.9
475
763.8
4514.6
1789.325
1857.850728
928.9253642
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Smooth Muscle Cell
Count
0
0
0
0
0

10
5
10
11
9

0

2.708012802
1.354006401
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Non-Ligated
Right Gracilis

Block Number
11-204 a
11-204 b
11-208
11-212
11-220
Average
Standard
Deviation
Standard Error

Proliferating
Cross-Sectional Smooth Muscle
Area (μm2)
Cell Count
238.3
422.2
687.4
827.7
126.2
460.36
295.3453792
132.0824689

Smooth Muscle Cell
Count
0
0
0
0
0
0

1
4
3
4
1
2.6

0
0

1.516575089
0.678232998

Non-Ligated
Right Muscular
Branch

Block Number
11-205
11-209
11-213
11-217
11-221
Average
Standard
Deviation
Standard Error

Cross-Sectional
Area (μm2)
1407.2
815.7
1786.3
1217
2616
1568.44

Proliferating
Smooth Muscle
Cell Count

682.0870274
305.038592

68

Smooth Muscle Cell
Count
0
0
0
0
0
0

5
6
8
6
10
7

0
0

2
0.894427191
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Day 14
Ligated Left
Gracilis

Block Number
11-246
11-254
11-258
11-262 a
11-262 b
11-264a a
11-264a b
Average
Standard
Deviation
Standard Error

CrossSectional
Proliferating Smooth Smooth Muscle
Area (μm2)
Muscle Cell Count
Cell Count
2074.7
0
7
890.7
0
5
2961.5
0
6
2262.2
0
5
3461.1
0
5
2545.9
0
7
1464.4
0
3
2237.214286
0
5.428571429
871.3161241
329.3265397

0
0

1.397276262
0.528120786

Ligated Left
Muscular
Branch

Block Number
11-195
11-251
11-255
11-259
11-263b
11-265
Average
Standard
Deviation
Standard Error

CrossSectional
Proliferating Smooth Smooth Muscle
2
Area (μm )
Muscle Cell Count
Cell Count
854.4
0
5
1762.6
0
9
2144.3
0
8
4539
0
8
1751.4
0
7
2382.4
0
9
2239.016667
0
7.666666667
1241.076914
506.6675283

0
0
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1.505545305
0.614636297
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Non-Ligated
Right Gracilis

Block Number
11-248
11-252
11-260
11-264b a
11-264b b
Average
Standard
Deviation
Standard Error

CrossSectional
Proliferating Smooth Smooth Muscle
2
Area (μm )
Muscle Cell Count
Cell Count
435
0
3
273.5
0
2
493.2
0
2
447.1
0
2
269.1
0
2
383.58
0
2.2
104.7838585
46.86076611

0
0

0.447213595
0.2

Non-Ligated
Right Muscular
Branch

Block Number
11-249
11-253
11-257
11-261
Average
Standard
Deviation
Standard Error

CrossSectional
Proliferating Smooth Smooth Muscle
Area (μm2)
Muscle Cell Count
Cell Count
2258.1
0
12
1028.4
0
7
1339.7
0
8
2032
0
7
1664.55
0
8.5
576.638376
288.319188

0
0
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2.380476143
1.190238071
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Statistical Data
Average Vessel Cross
Sectional Area (μm2)
LLG
LLMB
NLRG
NLRMB

Day 3 Day 7
Day 14
772.2
805.2 2237.2
1643.8 1789.3
2239
405.8
460.4
383.6
2176.3 1568.4 1664.6

Proliferating Smooth Muscle
Cells
LLG
LLMB
NLRG
NLRMB

Day 3
1.6
N/A
N/A
N/A

Day 7
2.5
N/A
N/A
N/A

Day 14
0
N/A
N/A
N/A

Smooth Muscle Cells
LLG
LLMB
NLRG
NLRMB

Day 3 Day 7
Day 14
3.3
3.7
5.4
8.2
9
7.7
1.8
2.6
2.2
9
7
8.5

ANOVA
ischemic Gracilis cross sectional area

NI gracilis cross sectional area
ischemic MB cross sectional area
NI mb cross sectional area

p-value
M1 vs M2 nonsignificant
M1 vs M3
P<.01
0.000135
M2 vs M3
P<.01
nonsignificant
0.829399
nonsignificant
0.666342
nonsignificant
0.666342

ischemic gracilis vsmcs
NI gracilis vsmcs
ischemic mb vsmcs
ni mb vsmcs
Proliferating vsmcs

nonsignificant?
nonsignificant
nonsignificant
nonsignificant
nonsignificant

71

0.041199
0.49327
0.697779
0.455587
0.088831
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T-Tests
NI = Nonischemic,
I = Ischemic
NI vs. I Gracilis Day 3 area
NI vs. I MB Day 3 area
NI vs. I Gracilis Day 3 SMCs
NI vs. I MB Day 3 SMCs
NI vs. I Gracilis D-7 area
NI vs. I MB Day 7 area
NI vs. I Gracilis Day 7 SMCs
NI vs. I MB Day 7 SMCs
NI vs. I Gracilis Day 14 area
NI vs. I MB Day 14 area
NI vs. I Gracilis Day 14 SMCs
NI vs. I MB Day 14 SMCs
MB vs Gracilis cross sectional
area
Day 3
Day 7
Day 14
MB vs gracilis vsmcs
Day 3
Day 7
Day 14
Proliferating vsmcs
day 3 vs 0
day 7 vs 0

p-value
0.052049
0.241757
0.012787
0.319311
0.035269
0.41617
0.168312
0.136281
0.000708
0.178619
0.000223
0.280574

0.002464
0.184761
0.498843
0.003183
0.00975
0.010033
0.000368
0.003374
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Vessel Composite Images
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2.
Suitable acknowledgment to the source must be made, either as a footnote
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“This article was published in Publication title, Vol number, Author(s), Title of article,
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3.
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4.
Reproduction of this material is confined to the purpose for which permission is
hereby given.
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